High-dose vitamin B12 slowed functional decline in an early ALS trial
Original source
Vitamin B12 and MND/ALS: Hope, science, and the impact of our genes. (opens in a new tab)You Nutrition Clinic has a commercial interest in this subject. Compass summarises the reporting; it is not independent analysis, and it is not clinical evidence.
In a Japanese clinical trial, injected high-dose methylcobalamin was linked to a 43% slower rate of functional decline in people with ALS who began treatment within one year of symptom onset. Japan’s medicines regulator approved methylcobalamin in 2024 to slow functional impairment in ALS. The source also discusses genetic differences that may affect B12 processing, but says these have not been shown to predict treatment response.
Why this matters
The findings suggest that high-dose injected B12 may help some people with early ALS, but slower decline is not the same as recovery or reversal. The evidence described here does not show that ordinary B12 supplements have the same effect, or that genetic testing can identify who will benefit. Treatment decisions should be based on clinical advice rather than this sponsored review alone.
Limitations and context
This is a sponsored expert review, not a primary research report. The source does not provide enough detail about the trial’s size, participant characteristics, or full results to assess the evidence independently. The genetic and laboratory findings are suggestive, and the source explicitly says they do not establish who will respond best. Promotional material about the clinic has been omitted.